Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
4.230
+0.010 (0.24%)
At close: Nov 7, 2025, 4:00 PM EST
4.230
0.00 (0.00%)
After-hours: Nov 7, 2025, 4:20 PM EST
Voyager Therapeutics Revenue
Voyager Therapeutics had revenue of $5.20M in the quarter ending June 30, 2025, a decrease of -82.42%. This brings the company's revenue in the last twelve months to $42.58M, down -70.38% year-over-year. In the year 2024, Voyager Therapeutics had annual revenue of $80.00M, down -68.00%.
Revenue (ttm)
$42.58M
Revenue Growth
-70.38%
P/S Ratio
5.77
Revenue / Employee
$247,558
Employees
172
Market Cap
234.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80.00M | -170.01M | -68.00% |
| Dec 31, 2023 | 250.01M | 209.10M | 511.16% |
| Dec 31, 2022 | 40.91M | 3.49M | 9.33% |
| Dec 31, 2021 | 37.42M | -133.71M | -78.14% |
| Dec 31, 2020 | 171.13M | 66.74M | 63.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VYGR News
- 2 months ago - Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 2 months ago - Voyager to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Voyager Reports Second Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 4 months ago - Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewsWire
- 5 months ago - Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewsWire
- 6 months ago - Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication - GlobeNewsWire
- 6 months ago - Voyager Reports First Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 6 months ago - Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting - GlobeNewsWire